MX2021012706A - Inhibidores de dihidroorotato deshidrogenasa. - Google Patents

Inhibidores de dihidroorotato deshidrogenasa.

Info

Publication number
MX2021012706A
MX2021012706A MX2021012706A MX2021012706A MX2021012706A MX 2021012706 A MX2021012706 A MX 2021012706A MX 2021012706 A MX2021012706 A MX 2021012706A MX 2021012706 A MX2021012706 A MX 2021012706A MX 2021012706 A MX2021012706 A MX 2021012706A
Authority
MX
Mexico
Prior art keywords
sup
dehydrogenase inhibitors
dihydroorotate dehydrogenase
compounds
dihydroorotate
Prior art date
Application number
MX2021012706A
Other languages
English (en)
Inventor
Zhuming Zhang
Scott Kuduk
Aihua Wang
Lindsey Deratt
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2021012706A publication Critical patent/MX2021012706A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos, composiciones y métodos para tratar enfermedades, trastornos o afecciones médicas que son afectados por la modulación de DHODH; tales compuestos se representan mediante la Fórmula (I) de la manera siguiente: en donde R1 , R2 , R3 , R4 , X y Y se definen en la presente descripción.
MX2021012706A 2019-04-17 2020-04-16 Inhibidores de dihidroorotato deshidrogenasa. MX2021012706A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835113P 2019-04-17 2019-04-17
PCT/IB2020/053601 WO2020212897A1 (en) 2019-04-17 2020-04-16 Dihydroorotate dehydrogenase inhibitors

Publications (1)

Publication Number Publication Date
MX2021012706A true MX2021012706A (es) 2022-01-31

Family

ID=70465152

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012706A MX2021012706A (es) 2019-04-17 2020-04-16 Inhibidores de dihidroorotato deshidrogenasa.

Country Status (22)

Country Link
US (2) US11505536B2 (es)
EP (1) EP3956320B1 (es)
JP (1) JP2022530203A (es)
KR (1) KR20220002964A (es)
CN (1) CN114174278A (es)
AR (1) AR118724A1 (es)
AU (1) AU2020259384A1 (es)
BR (1) BR112021020520A2 (es)
CA (1) CA3136791A1 (es)
CL (1) CL2021002681A1 (es)
CO (1) CO2021015264A2 (es)
CR (1) CR20210520A (es)
EC (1) ECSP21081726A (es)
ES (1) ES2968809T3 (es)
IL (1) IL287268A (es)
MA (1) MA55716A (es)
MX (1) MX2021012706A (es)
PE (1) PE20220761A1 (es)
SG (1) SG11202111179RA (es)
TW (1) TW202104207A (es)
UY (1) UY38670A (es)
WO (1) WO2020212897A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116804004A (zh) * 2020-07-14 2023-09-26 南京征祥医药有限公司 作为dhodh抑制剂的化合物
WO2022070068A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
WO2022074534A1 (en) * 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
EP4313150A1 (en) 2021-03-26 2024-02-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Pyrimidine biosynthesis inhibitor combination for use in treating viral infections
JP2024518497A (ja) 2021-05-11 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 併用療法
EP4337215A1 (en) 2021-05-11 2024-03-20 JANSSEN Pharmaceutica NV Combination therapies
CA3233973A1 (en) * 2021-10-13 2023-04-20 Dominic Reynolds Compounds and methods for modulating nucleic acid splicing
WO2023086799A1 (en) * 2021-11-09 2023-05-19 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1934094A (zh) * 2004-03-05 2007-03-21 万有制药株式会社 二芳基取代杂环5元环衍生物
JP2007015952A (ja) * 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
EP3640241B1 (en) * 2013-10-18 2022-09-28 Celgene Quanticel Research, Inc. Bromodomain inhibitors
ES2953347T3 (es) * 2014-09-19 2023-11-10 Forma Therapeutics Inc Derivados de piridin-2(1H)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante
PE20171179A1 (es) 2014-12-18 2017-08-22 Takeda Pharmaceuticals Co Formas en estado solido de pirrolidinonas heteroaromaticas fusionadas
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018077944A2 (en) 2016-10-27 2018-05-03 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
AU2018223982B2 (en) 2017-02-24 2022-02-03 Merck Patent Gmbh 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
AU2019242626A1 (en) 2018-03-26 2020-09-24 Clear Creek Bio, Inc. Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite
TW202043208A (zh) 2019-01-11 2020-12-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
AU2020218154A1 (en) * 2019-02-07 2021-08-05 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors

Also Published As

Publication number Publication date
EP3956320A1 (en) 2022-02-23
ECSP21081726A (es) 2021-12-30
TW202104207A (zh) 2021-02-01
SG11202111179RA (en) 2021-11-29
CA3136791A1 (en) 2020-10-22
US11753393B2 (en) 2023-09-12
PE20220761A1 (es) 2022-05-16
UY38670A (es) 2020-10-30
EP3956320B1 (en) 2023-11-29
AR118724A1 (es) 2021-10-27
US20200331881A1 (en) 2020-10-22
ES2968809T3 (es) 2024-05-14
CO2021015264A2 (es) 2021-11-19
MA55716A (fr) 2022-02-23
IL287268A (en) 2021-12-01
BR112021020520A2 (pt) 2021-12-07
WO2020212897A1 (en) 2020-10-22
AU2020259384A1 (en) 2021-11-11
CR20210520A (es) 2021-12-20
US11505536B2 (en) 2022-11-22
US20220298137A1 (en) 2022-09-22
KR20220002964A (ko) 2022-01-07
JP2022530203A (ja) 2022-06-28
CN114174278A (zh) 2022-03-11
CL2021002681A1 (es) 2022-05-27

Similar Documents

Publication Publication Date Title
MX2021012706A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2021008400A (es) Inhibidores de dihidroorotato deshidrogenasa.
TN2019000192A1 (en) Pyrazole derivatives as malt1 inhibitors
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2021014350A (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
MX2023007192A (es) Inhibidores de prmt5.
PH12017500829A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
MX2010002258A (es) Compuestos terapeuticos de isoxazol.
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
MX2020013899A (es) Derivados de pirazol como inhibidores de malt1.
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2020013699A (es) Derivados de pirazol como inhibidores de malt1.
MX2020008116A (es) Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2022009535A (es) Compuestos heterociclicos como inhibidores de la dihidrorotata deshidrogenasa.
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
WO2019175799A3 (en) Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
MX2023008968A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
MX2022002470A (es) Inhibidores de dihidroorotato deshidrogenasa sustituidos con urea.
MX2021009142A (es) Inhibidores topicos de fosfoinositol 3-cinasas.
MX2021000625A (es) Dinucleotidos ciclicos como agonistas de sting.